Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
ASH 2018: Expert overview of the latest in CLL, ALL and AML

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.12.18
Views: 194
Rating:

Prof Robin Foa - University of Rome, Rome, Italy

Prof Robin Foa speaks to ecancer at ASH 2018 about the latest in CLL, ALL and AML and hot topics from the meeting.

He says that after decades of work he hopes that now is a turning point for immunotherapy, made clear by the work presented at the meeting particularly in CAR T-Cell therapies. He also speaks about exciting trials for Ph-positive ALL patients and the multiple studies being presented at the meeting on combination therapies without chemotherapy.

Prof Foa remarks that targeted therapies without systemic chemotherapy are developing at an extraordinary pace, but the sustainability and reality of treatments reaching patients needs to be kept in mind.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content. 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation